Cadonilimab Injection，卡度尼利单抗注射液. 商品名：开坦尼.

On June 29, 2022, the China National Medical Products Administration announced that it has approved the new drug application for Katanib (cardunilimab injection), the world’s first PD-1/CTLA-4 bispecific antibody tumor immunotherapy drug independently developed by Kangfang Bio, for the treatment of patients with recurrent or metastatic cervical cancer (R/MCC) who have failed previous platinum-containing chemotherapy. Katanib is the world’s first tumor dual immune checkpoint inhibitor bispecific antibody approved for marketing. This approval will fill the gap in immunotherapy for advanced cervical cancer in China, and also fill the gap in the development of new bispecific antibody drugs in China.